Kei Ihira
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kei Ihira has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Hidemichi Watari
Department of Obstetrics and Gynecology, Hokkaido University Graduate School of Medicine and Faculty of Medicine, Sapporo, Japan
5 shared publications - Daisuke Aoki
Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan
2 shared publications - Daisuke Shintani
Department of Gynecology Oncology, Saitama Medical University International Medical Center, Hidaka, Japan
2 shared publications - Hiroshi Yagi
Department of Obstetrics and Gynecology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
2 shared publications - Ichinosuke Hyodo
Department of Gastrointestinal Medical Oncology, NHO Shikoku Cancer Center, Matsuyama, Japan
2 shared publications - Kazuhiro Takehara
Department of Gynecology, NHO Shikoku Cancer Center, Matsuyama, Japan
2 shared publications
Latest Publications
- Open Access
- 1 January 2027
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 38
cfDNA-inferred putative clonal hematopoiesis during first-line platinum-to-PARP inhibitor maintenance in ovarian cancer
Okazawa-Sakai M, et al. J Gynecol Oncol. 2027 ;38:e11. https://doi.org/10.3802/jgo.2027.38.e11
- 1 January 2027
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 38
Open AccesscfDNA-inferred putative clonal hematopoiesis during first-line platinum-to-PARP inhibitor maintenance in ovarian cancer
Okazawa-Sakai M, et al. J Gynecol Oncol. 2027 ;38:e11. https://doi.org/10.3802/jgo.2027.38.e11
- Open Access
- 1 January 2025
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 36 (3)
Gut microbiome associated with PARP inhibitor efficacy in patients with ovarian cancer
Okazawa-Sakai M, et al. J Gynecol Oncol. 2024 Oct;36:e38. https://doi.org/10.3802/jgo.2025.36.e38
- 1 January 2025
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 36 (3)
Open AccessGut microbiome associated with PARP inhibitor efficacy in patients with ovarian cancer
Okazawa-Sakai M, et al. J Gynecol Oncol. 2024 Oct;36:e38. https://doi.org/10.3802/jgo.2025.36.e38
- 29 September 2022
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 48 (12) , 3209-3218
Patterns and predictors of site‐specific recurrence in cervical cancer after radical hysterectomy
Aim: This study examines patterns and predictors of site‐specific recurrence to explore the causes of local recurrence of cervical cancer.Methods: Radical hysterectomy was performed in 121 patients (stage IB–IIB). Nerve‐sparing was performed whenever possible. The first recurrence in local, regional, and distant areas was examined. We investigated the possibility of nerve involvement in local recurrence, focusing on paravaginal tissues containing the pelvic plexus. We provide Supporting Information on local recurrence in the paravaginal area.Results: Local recurrence was an independent event from regional or distant recurrence. Local recurrence was seen only in high‐risk patients, while regional and distant recurrences were not or less related to the risk category. The independent risk factors by logistic regression for local, regional, and distant recurrence were parametrial invasion, vaginal invasion, and lymph node metastasis, respectively. Local recurrence showed a comparable or more significant negative impact on survival than distant recurrence. Among seven patients with local recurrences, five had a recurrence in the paravagina. The rate of paravaginal recurrence was one in 76 early‐stage and four in 45 locally advanced diseases. Four sites of paravaginal recurrence occurred on the nerve‐sparing side and two on the non‐nerve‐sparing side. Supporting Information demonstrated histological evidence of perineural spread into the pelvic plexus and perineural invasion of the primary tumor.Conclusions: A high percentage of local recurrences are in paravaginal tissue containing the pelvic plexus. The causal association of nerve‐sparing surgery and perineural invasion with local recurrence needs to be investigated in large prospective studies.
- 29 September 2022
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 48 (12) , 3209-3218
Patterns and predictors of site‐specific recurrence in cervical cancer after radical hysterectomy
Aim: This study examines patterns and predictors of site‐specific recurrence to explore the causes of local recurrence of cervical cancer.Methods: Radical hysterectomy was performed in 121 patients (stage IB–IIB). Nerve‐sparing was performed whenever possible. The first recurrence in local, regional, and distant areas was examined. We investigated the possibility of nerve involvement in local recurrence, focusing on paravaginal tissues containing the pelvic plexus. We provide Supporting Information on local recurrence in the paravaginal area.Results: Local recurrence was an independent event from regional or distant recurrence. Local recurrence was seen only in high‐risk patients, while regional and distant recurrences were not or less related to the risk category. The independent risk factors by logistic regression for local, regional, and distant recurrence were parametrial invasion, vaginal invasion, and lymph node metastasis, respectively. Local recurrence showed a comparable or more significant negative impact on survival than distant recurrence. Among seven patients with local recurrences, five had a recurrence in the paravagina. The rate of paravaginal recurrence was one in 76 early‐stage and four in 45 locally advanced diseases. Four sites of paravaginal recurrence occurred on the nerve‐sparing side and two on the non‐nerve‐sparing side. Supporting Information demonstrated histological evidence of perineural spread into the pelvic plexus and perineural invasion of the primary tumor.Conclusions: A high percentage of local recurrences are in paravaginal tissue containing the pelvic plexus. The causal association of nerve‐sparing surgery and perineural invasion with local recurrence needs to be investigated in large prospective studies.
- Open Access
- 23 April 2020
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 50 (8) , 882-888
Four versus six chemotherapy cycles in endometrial carcinoma with a high risk of recurrence: a retrospective study
Objective: This study compared the survival outcomes and the incidence of chemotherapy-related adverse events in endometrial cancer patients who received four and six cycles of adjuvant chemotherapy to examine the optimal number of adjuvant chemotherapy cycles. Methods: A total of 112 patients with endometrial cancer with a high risk of recurrence were retrospectively enrolled; 46 patients received four cycles and 66 received six cycles of adjuvant chemotherapy. Between-group differences of overall survival, disease-free survival, hematological and non-hematological toxicities were analyzed. Baseline patient’s background differences were assessed with inverse probability of treatment weighting using propensity score. Results: Overall and disease-free survivals between the two groups were not significantly different. Paclitaxel + carboplatin, every 3–4 weeks was the most frequently used chemotherapy regimen in both groups. Patients in the six-cycle chemotherapy group developed neutropenia G4 or febrile neutropenia more frequently than those in the four-cycle group; odds ratio (95% confidence interval) is 4.07 (1.51–10.96). Peripheral sensory neuropathy was the most frequently observed non-hematological toxicity; the incidence of peripheral sensory neuropathy was not significantly different between four- and six-cycle chemotherapy group, P = 0.832. The result was same in the subgroup analysis in patients who received TC regimen, P = 0.455. Conclusion: This study implies a possible benefit of fewer cycles of adjuvant chemotherapy in endometrial cancer patients with a high risk of recurrence because of the lower incidence of hematological toxicities without impairing survival outcomes.
- 23 April 2020
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 50 (8) , 882-888
Open AccessFour versus six chemotherapy cycles in endometrial carcinoma with a high risk of recurrence: a retrospective study
Objective: This study compared the survival outcomes and the incidence of chemotherapy-related adverse events in endometrial cancer patients who received four and six cycles of adjuvant chemotherapy to examine the optimal number of adjuvant chemotherapy cycles. Methods: A total of 112 patients with endometrial cancer with a high risk of recurrence were retrospectively enrolled; 46 patients received four cycles and 66 received six cycles of adjuvant chemotherapy. Between-group differences of overall survival, disease-free survival, hematological and non-hematological toxicities were analyzed. Baseline patient’s background differences were assessed with inverse probability of treatment weighting using propensity score. Results: Overall and disease-free survivals between the two groups were not significantly different. Paclitaxel + carboplatin, every 3–4 weeks was the most frequently used chemotherapy regimen in both groups. Patients in the six-cycle chemotherapy group developed neutropenia G4 or febrile neutropenia more frequently than those in the four-cycle group; odds ratio (95% confidence interval) is 4.07 (1.51–10.96). Peripheral sensory neuropathy was the most frequently observed non-hematological toxicity; the incidence of peripheral sensory neuropathy was not significantly different between four- and six-cycle chemotherapy group, P = 0.832. The result was same in the subgroup analysis in patients who received TC regimen, P = 0.455. Conclusion: This study implies a possible benefit of fewer cycles of adjuvant chemotherapy in endometrial cancer patients with a high risk of recurrence because of the lower incidence of hematological toxicities without impairing survival outcomes.
- Open Access
- 1 January 2018
- Published by Japan Society of Gynecologic and Obstetric Endoscopy and Minimally Invasive Therapy in JAPANESE JOURNAL OF GYNECOLOGIC AND OBSTETRIC ENDOSCOPY
- Vol. 34 (1) , 128-133
Laparoscopic surgery in osteogenesis imperfecta (OI) patient with tubo-ovarian abscess (TOA): A case report
総合学術電子ジャーナルサイト「J-STAGE」-国内で発行された学術論文全文を読むことのできる、日本最大級の総合電子ジャーナルプラットフォームです。
- 1 January 2018
- Published by Japan Society of Gynecologic and Obstetric Endoscopy and Minimally Invasive Therapy in JAPANESE JOURNAL OF GYNECOLOGIC AND OBSTETRIC ENDOSCOPY
- Vol. 34 (1) , 128-133
Open AccessLaparoscopic surgery in osteogenesis imperfecta (OI) patient with tubo-ovarian abscess (TOA): A case report
総合学術電子ジャーナルサイト「J-STAGE」-国内で発行された学術論文全文を読むことのできる、日本最大級の総合電子ジャーナルプラットフォームです。